Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis to sell Enablex US rights to Warner Chilcott
As per the terms of the deal, Warner Chilcott assumes rights to solely promote and develop Enablex for the US. While, Novartis retains the rights to Darifenacin worldwide,
As per the terms of the deal, Warner Chilcott assumes rights to solely promote and develop Enablex for the US. While, Novartis retains the rights to Darifenacin worldwide,
AMT-080 has shown efficacy in studies of a preclinical model of DMD. The proof of concept studies demonstrated that AMT’s technology resulted in functional dystrophin synthesis in both
The PERfECT Stent (A Prospective, Randomised Trial Evaluating a Paclitaxel-Eluting Balloon in Patients Treated with Endothelial Progenitor Cell Capturing Stents for De Novo Coronary Artery Disease) study compared
Aurobindo Pharma claims that Ampicillin & Sulbactam for injection USP is a Sterile Semi Synthetic Penicillin (SSP) product falling under the anti-infective segment and is generic equivalent to
The ISO 13485:2003 quality standard is recognised as the international standard for quality management systems specific to the design, development and production of medical devices. iTech Medical president
OmniComm provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. AE Reporting is an advanced adverse event reporting
As a vice president of Corporate Development, Xing Shen will oversee the company’s strategic business development and internal investor relations functions. Prior to his tenure with Lotus Pharma,
Most recently, Cohen worked as the chief scientific officer in Rosetta Genomics, a developer of microRNA-based molecular diagnostics. Asterand CEO Martyn Coombs said that Cohen has a reputation
Abstral is a rapidly-disintegrating tablet for sublingual administration of fentanyl intended for the management of breakthrough pain in cancer patients who are already receiving opioid analgesics for their
Nutrition 21 has posted a net loss of $3.66m for the full year ended 30 June 2010, or $0.04 loss per diluted share, compared to a net loss